[Low-molecular weight heparins. Prospects in 1985].
Interaction of low molecular weight heparin (LMW-Hep) along with coagulation system is characterized through an increase of the proportion between activity anti-Xa and anticoagulation activity. In animals, their antithrombotic role can be compared with the heparin one. Longer life of the biological effect (close to 100 p. 100) enables to act subcutaneously as well as to reduce posology: only one injection is then required so as to prevent from post-operative thrombosis. There are neither method nor international standard to control preparations efficacy. At the moment, posologies are better to be expressed in mg. Trials are assessed in the treatments of thrombosis with results increasing therapeutic efficacy. Too high posologies did supply hemorrhagic syndromes in surgical patients. A biological survey is thus required. As usual tests, such as "time" of cephalin are slightly sensible to LMW-Hep, only anti-Xa activity can be used. LMW-Hep with a low anticoagulant action thus demonstrate a new concept of antithrombotic therapy.
D000818:Animals; D006493:Heparin / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008970:Molecular Weight
D006493:Heparin
Les héparines de bas poids moléculaire. Perspectives en 1985.